LVP III Partners LP 4
4 · OncoMed Pharmaceuticals Inc · Filed Jul 23, 2013
Insider Transaction Report
Form 4
LVP GP I, LLC
10% Owner
Transactions
- Conversion
Common Stock
[F1][F2][F3]2013-07-23+100,000→ 100,000 total(indirect: Directly owned by LVP I) - Conversion
Common Stock
[F1][F2][F3]2013-07-23+65,476→ 165,476 total(indirect: Directly owned by LVP I) - Conversion
Common Stock
[F1][F2][F3]2013-07-23+74,142→ 239,618 total(indirect: Directly owned by LVP I) - Purchase
Common Stock
[F2][F3]2013-07-23$17.00/sh+7,937$134,929→ 247,555 total(indirect: Directly owned by LVP I) - Conversion
Common Stock
[F1][F2][F3]2013-07-23+426,315→ 426,315 total(indirect: Directly owned by LVP II) - Conversion
Common Stock
[F1][F2][F3]2013-07-23+279,135→ 705,450 total(indirect: Directly owned by LVP II) - Conversion
Common Stock
[F1][F2][F3]2013-07-23+316,079→ 1,021,529 total(indirect: Directly owned by LVP II) - Purchase
Common Stock
[F2][F3]2013-07-23$17.00/sh+33,834$575,178→ 1,055,363 total(indirect: Directly owned by LVP II) - Conversion
Common Stock
[F1][F2][F3]2013-07-23+611,995→ 611,995 total(indirect: Directly owned by LVP III) - Conversion
Common Stock
[F1][F2][F3]2013-07-23+692,994→ 1,304,989 total(indirect: Directly owned by LVP III) - Purchase
Common Stock
[F2][F3]2013-07-23$17.00/sh+43,223$734,791→ 1,348,212 total(indirect: Directly owned by LVP III) - Conversion
Common Stock
[F1][F2][F3]2013-07-23+30,599→ 30,599 total(indirect: Directly owned by Associates) - Conversion
Common Stock
[F1][F2][F3]2013-07-23+34,649→ 65,248 total(indirect: Directly owned by Associates) - Purchase
Common Stock
[F2][F3]2013-07-23$17.00/sh+2,161$36,737→ 67,409 total(indirect: Directly owned by Associates) - Conversion
Common Stock
[F1][F2][F3]2013-07-23+15,299→ 15,299 total(indirect: Directly owned by Partners) - Conversion
Common Stock
[F1][F2][F3]2013-07-23+17,324→ 32,623 total(indirect: Directly owned by Partners) - Purchase
Common Stock
[F2][F3]2013-07-23$17.00/sh+1,080$18,360→ 33,703 total(indirect: Directly owned by Partners) - Conversion
Series A Preferred Stock
[F1][F4][F5][F2][F3]2013-07-23−100,000→ 0 total(indirect: Directly owned by LVP I)→ Common Stock (100,000 underlying) - Conversion
Series A Preferred Stock
[F1][F4][F5][F2][F3]2013-07-23−426,315→ 0 total(indirect: Directly owned by LVP II)→ Common Stock (426,315 underlying) - Conversion
Series B Preferred Stock
[F1][F4][F5][F2][F3]2013-07-23−65,476→ 0 total(indirect: Directly owned by LVP I)→ Common Stock (65,476 underlying) - Conversion
Series B Preferred Stock
[F1][F4][F5][F2][F3]2013-07-23−279,135→ 0 total(indirect: Directly owned by LVP II)→ Common Stock (279,135 underlying) - Conversion
Series B Preferred Stock
[F1][F4][F5][F2][F3]2013-07-23−611,995→ 0 total(indirect: Directly owned by LVP III)→ Common Stock (611,995 underlying) - Conversion
Series B Preferred Stock
[F1][F4][F5][F2][F3]2013-07-23−30,599→ 0 total(indirect: Directly owned by Associates)→ Common Stock (30,599 underlying) - Conversion
Series B Preferred Stock
[F1][F4][F5][F2][F3]2013-07-23−15,299→ 0 total(indirect: Directly owned by Partners)→ Common Stock (15,299 underlying) - Conversion
Series B-1 Preferred Stock
[F1][F4][F5][F2][F3]2013-07-23−74,142→ 0 total(indirect: Directly owned by LVP I)→ Common Stock (74,142 underlying) - Conversion
Series B-1 Preferred Stock
[F1][F4][F5][F2][F3]2013-07-23−316,079→ 0 total(indirect: Directly owned by LVP II)→ Common Stock (316,079 underlying) - Conversion
Series B-1 Preferred Stock
[F1][F4][F5][F2][F3]2013-07-23−692,994→ 0 total(indirect: Directly owned by LVP III)→ Common Stock (692,994 underlying) - Conversion
Series B-1 Preferred Stock
[F1][F4][F5][F2][F3]2013-07-23−34,649→ 0 total(indirect: Directly owned by Associates)→ Common Stock (34,649 underlying) - Conversion
Series B-1 Preferred Stock
[F1][F4][F5][F2][F3]2013-07-23−17,324→ 0 total(indirect: Directly owned by Partners)→ Common Stock (17,324 underlying)
Holdings
- 43,859(indirect: Directly owned by LVPMC)
Common Stock
[F2][F3]
Footnotes (5)
- [F1]Each share of Series A, Series B and Series B-1 Preferred Stock automatically converted on a one-to-one basis into Common Stock immediately prior to the consummation of the Issuer's initial public offering on July 23, 2013.
- [F2]The reported securities are owned directly by each of LVPMC, LLC ("LVPMC"), LVP Life Science Ventures I, L.P. ("LVP I"), LVP Life Science Ventures II, L.P. ("LVP II"), LVP Life Science Ventures III, L.P ("LVP III"), LVP III Associates, L.P. ("Associates") and LVP III Partners, L.P. ("Partners"). LVP GP I, LLC ("GP I") is the general partner of LVP I, LVP GP II, LLC ("GP II") is the general partner of LVP II and LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates and Partners. (Continued on Footnote 3)
- [F3]GP I, GP II and GP III may be deemed to have sole voting power and dispositive power over the shares held by LVP I, LVP II, LVP III, Associates and Partners. Each of GP I, GP II, GP III and Patrick Latterell, the managing member of each of GP I, GP II and GP III and the manager of LVPMC may be deemed to share voting and dispositive power over the reported securities and disclaim beneficial ownership of the reported securities held by LVPMC, LVP I, LVP II, LVP III, Associates and Partners except to the extent of any pecuniary interest therein. James W. Woody, M.D., Ph.D., as a member of each of GP I, GP II and GP III, may be deemed to share voting and dispositive power over the reported securities held by LVP I, LVP II, LVP III, Associates and Partners, and disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
- [F4]The securities are immediately convertible.
- [F5]The expiration date is not relevant to the conversion of these securities.